Print full article

Pharmaceutical companies partner to research ocular cannabidiol-based drug for dogs

The clinical research application was presented to the veterinary drugs directorate at Health Canada

Suggested Veterinary Products

researchTetra Bio-Pharma Inc., and Panag Pharma Inc., have submitted a clinical research application to examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines.

The companies presented the application to the veterinary drugs directorate at Health Canada.

“Several companies are marketing cannabis-based treatments for ailments in companion animals, but there is a major gap in understanding the safety and efficacy of these drugs,” said Guy Chamberland, M.Sc., PhD, chief executive officer and chief security officer of Tetra Bio-Pharma.

“Tetra continues to adhere to an evidence-based drug development model, consistent with bringing novel, efficacious, and safe drug products to market, including the veterinary market. We look forward to launching this trial to investigate the use of cannabinoids to treat eye pain and inflammation in dogs.”

The pilot study will be led by veterinary ocular care specialists.

Leave a Comment



Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.